Join Michael Hochman, MD, MPH, for the second episode of Updates in Slow Medicine. This installment discusses results from a recent study that raises the possibility that a…
NEW YORK (Reuters Health) – Silent embolic cerebral infarctions occur in about 1 in 6 patients after undergoing coronary angiography, and the risk is related to the degree…
NEW YORK (Reuters Health) – For primary percutaneous coronary intervention for ST-segment elevation MI, access via the radial artery is associated with better outcomes than is the femoral…
NEW YORK (Reuters Health) – For patients with significant mitral valve regurgitation who are not considered candidates for surgery, catheter-based mitral leaflet repair with the MitraClip device (Abbott…
NEW YORK (Reuters Health) – In patients undergoing percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI), triple antithrombotic therapy significantly increases the risk of major bleeding compared…
NEW YORK (Reuters Health) – Long-term outcomes are better for patients with three-vessel coronary artery disease when they undergo off-pump coronary artery bypass grafting rather than percutaneous coronary…
NEW YORK (Reuters Health) – Overall outcomes of drug-eluting coronary stent (DES) implantation are statistically no worse with 6 months of dual antiplatelet therapy than with 12 months,…
NEW YORK (Reuters Health) Pooled data from four relatively small but high-quality prospective randomized controlled studies suggest an advantage to intracoronary (IC) over intravenous (IV) administration of abciximab…
NEW YORK (Reuters Health) – Performing percutaneous coronary interventions for coronary artery disease is feasible before transcatheter aortic valve implantation (TAVI), and the strategy appears safe, according to…
NEW YORK (Reuters Health) – High-dose daptomycin appears to be a safe and effective therapeutic option for cardiac implantable electronic device (CIED)-related infective endocarditis due to staphylococci, clinicians…
NEW YORK (Reuters Health) – Results of an updated meta-analysis indicate that there are no clinically relevant differences in efficacy or effectiveness among second-generation antidepressants used to treat…
